EXAS Stock Overview
Provides cancer screening and diagnostic test products in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
Exact Sciences Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$59.40 |
| 52 Week High | US$79.62 |
| 52 Week Low | US$40.62 |
| Beta | 1.23 |
| 1 Month Change | 12.27% |
| 3 Month Change | -14.70% |
| 1 Year Change | -19.19% |
| 3 Year Change | -23.96% |
| 5 Year Change | -36.88% |
| Change since IPO | 302.71% |
Recent News & Updates
Recent updates
Why Investors Shouldn't Be Surprised By Exact Sciences Corporation's (NASDAQ:EXAS) 27% Share Price Plunge
Nov 10
We Think Exact Sciences (NASDAQ:EXAS) Has A Fair Chunk Of Debt
Sep 25Exact Sciences: Cost Optimization And Product Strength
Aug 18Exact Sciences Corporation's (NASDAQ:EXAS) Share Price Boosted 27% But Its Business Prospects Need A Lift Too
Aug 14Exact Sciences: Still No Reason To Own
Jun 11Revenues Working Against Exact Sciences Corporation's (NASDAQ:EXAS) Share Price Following 27% Dive
Jun 02An Intrinsic Calculation For Exact Sciences Corporation (NASDAQ:EXAS) Suggests It's 46% Undervalued
Feb 23Investors Don't See Light At End Of Exact Sciences Corporation's (NASDAQ:EXAS) Tunnel
Jan 08Shareholder Returns
| EXAS | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -3.0% | -3.6% | -2.4% |
| 1Y | -19.2% | -2.7% | 23.3% |
Return vs Industry: EXAS underperformed the US Biotechs industry which returned -2.7% over the past year.
Return vs Market: EXAS underperformed the US Market which returned 23.3% over the past year.
Price Volatility
| EXAS volatility | |
|---|---|
| EXAS Average Weekly Movement | 8.9% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: EXAS has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: EXAS's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | 6,550 | Kevin Conroy | www.exactsciences.com |
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.
Exact Sciences Corporation Fundamentals Summary
| EXAS fundamental statistics | |
|---|---|
| Market cap | US$10.99b |
| Earnings (TTM) | -US$214.04m |
| Revenue (TTM) | US$2.69b |
4.1x
P/S Ratio-51.4x
P/E RatioIs EXAS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EXAS income statement (TTM) | |
|---|---|
| Revenue | US$2.69b |
| Cost of Revenue | US$727.88m |
| Gross Profit | US$1.96b |
| Other Expenses | US$2.18b |
| Earnings | -US$214.04m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.16 |
| Gross Margin | 72.96% |
| Net Profit Margin | -7.95% |
| Debt/Equity Ratio | 80.0% |
How did EXAS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 02:06 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Exact Sciences Corporation is covered by 46 analysts. 23 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Catherine Ramsey Schulte | Baird |
| Raymond Myers | Benchmark Company |
| Bruce Jackson | Benchmark Company |